Sands Capital Life Sciences Pulse Fund II, L.P. — SEC Form 4 filings
SEC reporting owner CIK 1875620. 1 Form 4 filing on record with FilingPulse; latest filed 2025-11-24.
Transaction summary — filings shown
Covers all 1 filing on record, filed 2025-11-24 to 2025-11-24. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 2,068,965 shares, $2,999,999 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: purchase of 2,068,965 shares @ $1.45 ($2,999,999) in Inhibikase Therapeutics, Inc., filed 2025-11-24.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | 10% owner | 1 | 1 leg · 2,068,965 sh · $2,999,999 | — | — |
Form 4 filings — Sands Capital Life Sciences Pulse Fund II, L.P.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2025-11-24 | 4 | Inhibikase Therapeutics, Inc. (IKT) jointly with Sands Capital Alternatives, LLC, SANDS FRANK M. | Purchase (P): 2,068,965 @ $1.45 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1875620 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →